Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298916 · ClinicalTrials.gov registry record · Phase 1
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
A Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by Lantheus Medical Imaging.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 5
- Study locations
NCT06298916 is a Phase 1 study of Colorectal Cancer and Pancreatic Cancer that is actively recruiting participants, run by Lantheus Medical Imaging. The registered enrollment target is 26 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT06298916, a Phase 1 study of Colorectal Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by Lantheus Medical Imaging.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
Conditions Studied
Interventions
- COMBINATION_PRODUCT 64Cu-LNTH-1363S
Study Locations (5)
California
- City of Hope - Duarte
- UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
- Stanford Hospital & Clinics - Stanford
Michigan
- BAMF Health, Inc. - Grand Rapids
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-08 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06298916
The ClinicalTrials.gov registry entry for NCT06298916 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which 64Cu-LNTH-1363S is the first listed.
NCT06298916 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT06298916 about?
NCT06298916 is a clinical study titled "64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer". This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients...
What is the current status of trial NCT06298916?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-08. Estimated completion is 2026-04.
What conditions does trial NCT06298916 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Sarcoma.
What interventions are being tested in trial NCT06298916?
The interventions under investigation include: 64Cu-LNTH-1363S (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06298916?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298916 being conducted?
This trial has 5 study locations across California, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.